UniProt ID | CSPG4_HUMAN | |
---|---|---|
UniProt AC | Q6UVK1 | |
Protein Name | Chondroitin sulfate proteoglycan 4 | |
Gene Name | CSPG4 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 2322 | |
Subcellular Localization |
Cell membrane Single-pass type I membrane protein Extracellular side . Apical cell membrane Single-pass type I membrane protein Extracellular side . Cell projection, lamellipodium membrane Single-pass type I membrane protein Extracellular side |
|
Protein Description | Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Functions also as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades.. | |
Protein Sequence | MQSGPRPPLPAPGLALALTLTMLARLASAASFFGENHLEVPVATALTDIDLQLQFSTSQPEALLLLAAGPADHLLLQLYSGRLQVRLVLGQEELRLQTPAETLLSDSIPHTVVLTVVEGWATLSVDGFLNASSAVPGAPLEVPYGLFVGGTGTLGLPYLRGTSRPLRGCLHAATLNGRSLLRPLTPDVHEGCAEEFSASDDVALGFSGPHSLAAFPAWGTQDEGTLEFTLTTQSRQAPLAFQAGGRRGDFIYVDIFEGHLRAVVEKGQGTVLLHNSVPVADGQPHEVSVHINAHRLEISVDQYPTHTSNRGVLSYLEPRGSLLLGGLDAEASRHLQEHRLGLTPEATNASLLGCMEDLSVNGQRRGLREALLTRNMAAGCRLEEEEYEDDAYGHYEAFSTLAPEAWPAMELPEPCVPEPGLPPVFANFTQLLTISPLVVAEGGTAWLEWRHVQPTLDLMEAELRKSQVLFSVTRGARHGELELDIPGAQARKMFTLLDVVNRKARFIHDGSEDTSDQLVLEVSVTARVPMPSCLRRGQTYLLPIQVNPVNDPPHIIFPHGSLMVILEHTQKPLGPEVFQAYDPDSACEGLTFQVLGTSSGLPVERRDQPGEPATEFSCRELEAGSLVYVHRGGPAQDLTFRVSDGLQASPPATLKVVAIRPAIQIHRSTGLRLAQGSAMPILPANLSVETNAVGQDVSVLFRVTGALQFGELQKQGAGGVEGAEWWATQAFHQRDVEQGRVRYLSTDPQHHAYDTVENLALEVQVGQEILSNLSFPVTIQRATVWMLRLEPLHTQNTQQETLTTAHLEATLEEAGPSPPTFHYEVVQAPRKGNLQLQGTRLSDGQGFTQDDIQAGRVTYGATARASEAVEDTFRFRVTAPPYFSPLYTFPIHIGGDPDAPVLTNVLLVVPEGGEGVLSADHLFVKSLNSASYLYEVMERPRHGRLAWRGTQDKTTMVTSFTNEDLLRGRLVYQHDDSETTEDDIPFVATRQGESSGDMAWEEVRGVFRVAIQPVNDHAPVQTISRIFHVARGGRRLLTTDDVAFSDADSGFADAQLVLTRKDLLFGSIVAVDEPTRPIYRFTQEDLRKRRVLFVHSGADRGWIQLQVSDGQHQATALLEVQASEPYLRVANGSSLVVPQGGQGTIDTAVLHLDTNLDIRSGDEVHYHVTAGPRWGQLVRAGQPATAFSQQDLLDGAVLYSHNGSLSPRDTMAFSVEAGPVHTDATLQVTIALEGPLAPLKLVRHKKIYVFQGEAAEIRRDQLEAAQEAVPPADIVFSVKSPPSAGYLVMVSRGALADEPPSLDPVQSFSQEAVDTGRVLYLHSRPEAWSDAFSLDVASGLGAPLEGVLVELEVLPAAIPLEAQNFSVPEGGSLTLAPPLLRVSGPYFPTLLGLSLQVLEPPQHGALQKEDGPQARTLSAFSWRMVEEQLIRYVHDGSETLTDSFVLMANASEMDRQSHPVAFTVTVLPVNDQPPILTTNTGLQMWEGATAPIPAEALRSTDGDSGSEDLVYTIEQPSNGRVVLRGAPGTEVRSFTQAQLDGGLVLFSHRGTLDGGFRFRLSDGEHTSPGHFFRVTAQKQVLLSLKGSQTLTVCPGSVQPLSSQTLRASSSAGTDPQLLLYRVVRGPQLGRLFHAQQDSTGEALVNFTQAEVYAGNILYEHEMPPEPFWEAHDTLELQLSSPPARDVAATLAVAVSFEAACPQRPSHLWKNKGLWVPEGQRARITVAALDASNLLASVPSPQRSEHDVLFQVTQFPSRGQLLVSEEPLHAGQPHFLQSQLAAGQLVYAHGGGGTQQDGFHFRAHLQGPAGASVAGPQTSEAFAITVRDVNERPPQPQASVPLRLTRGSRAPISRAQLSVVDPDSAPGEIEYEVQRAPHNGFLSLVGGGLGPVTRFTQADVDSGRLAFVANGSSVAGIFQLSMSDGASPPLPMSLAVDILPSAIEVQLRAPLEVPQALGRSSLSQQQLRVVSDREEPEAAYRLIQGPQYGHLLVGGRPTSAFSQFQIDQGEVVFAFTNFSSSHDHFRVLALARGVNASAVVNVTVRALLHVWAGGPWPQGATLRLDPTVLDAGELANRTGSVPRFRLLEGPRHGRVVRVPRARTEPGGSQLVEQFTQQDLEDGRLGLEVGRPEGRAPGPAGDSLTLELWAQGVPPAVASLDFATEPYNAARPYSVALLSVPEAARTEAGKPESSTPTGEPGPMASSPEPAVAKGGFLSFLEANMFSVIIPMCLVLLLLALILPLLFYLRKRNKTGKHDVQVLTAKPRNGLAGDTETFRKVEPGQAIPLTAVPGQGPPPGGQPDPELLQFCRTPNPALKNGQYWV | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
21 | Phosphorylation | LALALTLTMLARLAS HHHHHHHHHHHHHHH | 12.61 | 22817900 | |
130 | N-linked_Glycosylation | LSVDGFLNASSAVPG EEECCCCCCCCCCCC | 35.20 | UniProtKB CARBOHYD | |
163 | Phosphorylation | LPYLRGTSRPLRGCL CCCCCCCCCCCCCCC | 34.42 | - | |
348 | N-linked_Glycosylation | GLTPEATNASLLGCM CCCHHHHCHHHCHHH | 34.28 | UniProtKB CARBOHYD | |
427 | N-linked_Glycosylation | GLPPVFANFTQLLTI CCCCCCCCHHEEEEC | 29.09 | UniProtKB CARBOHYD | |
643 | Phosphorylation | QDLTFRVSDGLQASP CCCEEEECCCCCCCC | 23.00 | - | |
685 | N-linked_Glycosylation | AMPILPANLSVETNA CCCCCCCCCEEECCC | 30.80 | UniProtKB CARBOHYD | |
743 | Phosphorylation | VEQGRVRYLSTDPQH HHCCCEEEEECCCCC | 11.35 | - | |
772 | N-linked_Glycosylation | VGQEILSNLSFPVTI HHHHHHHCCCCCEEE | 35.94 | UniProtKB CARBOHYD | |
926 | Phosphorylation | ADHLFVKSLNSASYL CCEEEEEECCCCHHH | 27.73 | 22210691 | |
929 | Phosphorylation | LFVKSLNSASYLYEV EEEEECCCCHHHHHH | 24.72 | 22210691 | |
931 | Phosphorylation | VKSLNSASYLYEVME EEECCCCHHHHHHHH | 18.58 | 22210691 | |
932 | Phosphorylation | KSLNSASYLYEVMER EECCCCHHHHHHHHC | 17.02 | 22210691 | |
995 | O-linked_Glycosylation | ATRQGESSGDMAWEE EEECCCCCCCCHHHH | 34.21 | - | |
1131 | N-linked_Glycosylation | EPYLRVANGSSLVVP CCEEEECCCCEEEEC | 48.28 | UniProtKB CARBOHYD | |
1185 | Phosphorylation | VRAGQPATAFSQQDL CCCCCCCCCCCHHHH | 34.61 | 24719451 | |
1202 | N-linked_Glycosylation | GAVLYSHNGSLSPRD CCEEEEECCCCCCCC | 35.49 | UniProtKB CARBOHYD | |
1204 | Phosphorylation | VLYSHNGSLSPRDTM EEEEECCCCCCCCCE | 30.87 | 24719451 | |
1206 | Phosphorylation | YSHNGSLSPRDTMAF EEECCCCCCCCCEEE | 21.42 | 24719451 | |
1277 | Phosphorylation | PPADIVFSVKSPPSA CCHHEEEEECCCCCC | 20.10 | 23312004 | |
1364 | N-linked_Glycosylation | AIPLEAQNFSVPEGG CCCCCCCCCCCCCCC | 37.90 | UniProtKB CARBOHYD | |
1449 | N-linked_Glycosylation | DSFVLMANASEMDRQ CEEEEEECHHHCCCC | 29.99 | UniProtKB CARBOHYD | |
1457 | Phosphorylation | ASEMDRQSHPVAFTV HHHCCCCCCCEEEEE | 30.56 | 30257219 | |
1583 | Phosphorylation | AQKQVLLSLKGSQTL ECCEEEEEECCCCEE | 24.71 | 24719451 | |
1587 | Phosphorylation | VLLSLKGSQTLTVCP EEEEECCCCEEEECC | 20.57 | 24043423 | |
1589 | Phosphorylation | LSLKGSQTLTVCPGS EEECCCCEEEECCCC | 26.54 | 24043423 | |
1591 | Phosphorylation | LKGSQTLTVCPGSVQ ECCCCEEEECCCCCC | 24.37 | 24043423 | |
1596 | Phosphorylation | TLTVCPGSVQPLSSQ EEEECCCCCCCCCCC | 11.61 | 24043423 | |
1601 | Phosphorylation | PGSVQPLSSQTLRAS CCCCCCCCCCCHHHH | 27.38 | 24043423 | |
1602 | Phosphorylation | GSVQPLSSQTLRASS CCCCCCCCCCHHHHC | 34.56 | 24043423 | |
1604 | Phosphorylation | VQPLSSQTLRASSSA CCCCCCCCHHHHCCC | 21.84 | 24043423 | |
1645 | N-linked_Glycosylation | STGEALVNFTQAEVY CCCCEEEECEEEEEE | 34.79 | UniProtKB CARBOHYD | |
1857 | Phosphorylation | PISRAQLSVVDPDSA CCCCEEEEEECCCCC | 14.17 | 29507054 | |
1909 | N-linked_Glycosylation | GRLAFVANGSSVAGI CCEEEEECCCCEEEE | 45.65 | UniProtKB CARBOHYD | |
2016 | N-linked_Glycosylation | EVVFAFTNFSSSHDH EEEEEEECCCCCCCH | 28.48 | UniProtKB CARBOHYD | |
2034 | N-linked_Glycosylation | LALARGVNASAVVNV HHHHCCCCHHHEEHH | 30.88 | UniProtKB CARBOHYD | |
2036 | Phosphorylation | LARGVNASAVVNVTV HHCCCCHHHEEHHHH | 19.18 | - | |
2040 | N-linked_Glycosylation | VNASAVVNVTVRALL CCHHHEEHHHHHHHH | 19.69 | UniProtKB CARBOHYD | |
2042 | Phosphorylation | ASAVVNVTVRALLHV HHHEEHHHHHHHHHH | 10.08 | - | |
2075 | N-linked_Glycosylation | LDAGELANRTGSVPR ECHHHHHHCCCCCCC | 55.46 | 16335952 | |
2077 | Phosphorylation | AGELANRTGSVPRFR HHHHHHCCCCCCCEE | 33.35 | - | |
2079 | Phosphorylation | ELANRTGSVPRFRLL HHHHCCCCCCCEEEC | 28.47 | - | |
2203 | O-linked_Glycosylation | GEPGPMASSPEPAVA CCCCCCCCCCCCCHH | 39.93 | OGP | |
2204 | O-linked_Glycosylation | EPGPMASSPEPAVAK CCCCCCCCCCCCHHC | 24.60 | OGP | |
2252 | Phosphorylation | YLRKRNKTGKHDVQV HHHHHCCCCCCCEEE | 55.82 | - | |
2261 | Phosphorylation | KHDVQVLTAKPRNGL CCCEEEEEECCCCCC | 33.50 | 26699800 | |
2263 | Ubiquitination | DVQVLTAKPRNGLAG CEEEEEECCCCCCCC | 39.00 | 23000965 | |
2272 | Phosphorylation | RNGLAGDTETFRKVE CCCCCCCCCCCCCCC | 35.69 | 29255136 | |
2274 | Phosphorylation | GLAGDTETFRKVEPG CCCCCCCCCCCCCCC | 30.72 | 29255136 | |
2277 | Ubiquitination | GDTETFRKVEPGQAI CCCCCCCCCCCCCCC | 46.92 | 29967540 | |
2310 | Phosphorylation | ELLQFCRTPNPALKN HHHHHCCCCCCCCCC | 28.71 | 29255136 | |
2316 | Ubiquitination | RTPNPALKNGQYWV- CCCCCCCCCCCCCC- | 62.23 | 21963094 | |
2320 | Phosphorylation | PALKNGQYWV----- CCCCCCCCCC----- | 14.99 | 22461510 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
2252 | T | Phosphorylation | Kinase | PRKCA | P17252 | Uniprot |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CSPG4_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CSPG4_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
GRIP2_HUMAN | GRIP2 | physical | 12458226 | |
CDC42_HUMAN | CDC42 | physical | 10587647 | |
GRIP1_HUMAN | GRIP1 | physical | 12458226 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
N-linked Glycosylation | |
Reference | PubMed |
"Human plasma N-glycoproteome analysis by immunoaffinity subtraction,hydrazide chemistry, and mass spectrometry."; Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,Moore R.J., Smith R.D.; J. Proteome Res. 4:2070-2080(2005). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-2075, AND MASSSPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21, AND MASSSPECTROMETRY. |